{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:39:51Z","timestamp":1787013591722,"version":"build-2736575974"},"reference-count":25,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Secukinumab has been approved for the treatment of psoriasis. Off\u2010label high\u2010dose regimens have been used for certain patients. Therapeutic drug monitoring can assist in adjusting treatment plans. This study aimed to determine the therapeutic threshold of secukinumab and evaluate the influence of patient characteristics on secukinumab concentrations in patients with psoriasis. Patients with psoriasis (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200936) treated with secukinumab during the maintenance therapy were enrolled in this cross\u2010sectional study. Disease activity was determined using the psoriasis area and severity index (PASI) score, with an optimal response (OR) defined as \u2264\u20092. Secukinumab trough concentrations were measured using an in\u2010house developed sandwich ELISA method. The median secukinumab concentrations in patients with OR were significantly higher than in those without (35.08 vs. 25.94\u2009\u03bcg\/mL,\n                    <jats:italic>p\u2009&lt;<\/jats:italic>\n                    \u20090.05). Secukinumab levels greater than 35.43\u2009\u03bcg\/mL were associated with OR (sensitivity of 50.00%, specificity of 89.89%, AUC\u2009=\u20090.70 and\n                    <jats:italic>p\u2009&lt;<\/jats:italic>\n                    \u20090.05). Multivariate logistic regression showed that secukinumab concentrations were significantly associated with OR (odds ratio: 1.02; 95% CI: 1.01\u20131.12;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.04). Linear mixed\u2010effects analysis indicated that an increase in body weight and a decrease in albumin were associated with a decrease in secukinumab concentrations. IL\u201017A levels showed no correlation with PASI score or secukinumab concentrations. Secukinumab concentrations over 35.43\u2009\u03bcg\/mL were associated with OR in patients with psoriasis. When determining the treatment dose, attention may be paid to patients with higher body weight and lower albumin levels in order to prevent underdosing.\n                  <\/jats:p>","DOI":"10.1111\/1346-8138.17893","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T12:25:01Z","timestamp":1754396701000},"page":"1570-1575","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Relationships Between Secukinumab Concentrations, Disease Activity, and\n                    <scp>IL<\/scp>\n                    \u2010\n                    <scp>17A<\/scp>\n                    Levels in Psoriasis: A Cross\u2010Sectional Observational Study"],"prefix":"10.1111","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7302-1257","authenticated-orcid":false,"given":"Kouzhu","family":"Zhu","sequence":"first","affiliation":[{"name":"Department of Pharmacy Affiliated Children's Hospital to Jiangnan University (Wuxi Children's Hospital)  Jiangsu Wuxi China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Dermatology The Affiliated Wuxi People's Hospital of Nanjing Medical University  Jiangsu Wuxi China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Dermatology Jiangnan University Medical Center  Jiangsu Wuxi China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panyu","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Dermatology The Affiliated Wuxi People's Hospital of Nanjing Medical University  Jiangsu Wuxi China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3429-9584","authenticated-orcid":false,"given":"Yuanbo","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Dermatology The Affiliated Wuxi People's Hospital of Nanjing Medical University  Jiangsu Wuxi China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Dermatology The Affiliated Wuxi People's Hospital of Nanjing Medical University  Jiangsu Wuxi China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Affiliated Children's Hospital to Jiangnan University (Wuxi Children's Hospital)  Jiangsu Wuxi China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2172-4406","authenticated-orcid":false,"given":"Lei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology The Affiliated Wuxi People's Hospital of Nanjing Medical University  Jiangsu Wuxi China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.02.039"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14890"},{"key":"e_1_2_9_4_1","unstructured":"Anon \u201cCosentyx | European Medicines Agency (EMA) \u201d2015 accessed November 25 2024 https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cosentyx."},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18143"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20971"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2019.04.012"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/ced.15157"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.06.038"},{"key":"e_1_2_9_10_1","first-page":"1249","article-title":"Early\u2010Effect of Anti\u2010IL\u201017A for Serum Inflammation Related Cytokines Levels in Patients With Psoriasis Vulgaris","volume":"34","author":"Zhang L.","year":"2020","journal-title":"Chinese Journal of Dermatovenereology"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/cimb46070457"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20096"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.05.594"},{"key":"e_1_2_9_14_1","first-page":"1267","article-title":"Determination of Secukinumab in Human Plasma by ELISA Method and Application in Psoriasis Patients","volume":"29","author":"Dai Y.","year":"2024","journal-title":"Chinese Journal of Clinical Pharmacology and Therapeutics"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/3762651"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000713"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19782"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1832649"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/1203475419843118"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412679"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1430120"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14971"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2006.09.001"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.42921"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12725"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.04.029"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.17893","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T14:55:29Z","timestamp":1764168929000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.17893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1111\/1346-8138.17893"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.17893","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,5]]},"assertion":[{"value":"2025-02-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}